Mikronos Biyomedikal

About This Project

Founded in 2019 with TÜBİTAK BİGG support, MİKRONOS Biomedical develops clotting measurement technologies to help patients with bleeding disorders survive.

A significant portion of patients with severe bleeding from organ transplants, work, and traffic accidents may have serious clotting problems. As a result, more than 5 million preventable deaths occur worldwide every year. In the global clotting tests market, which exceeds 1.5 billion dollars today, MİKRONOS’s target market includes public and university laboratories, hospitals, and ambulance services.